HRP20110875T1 - Glepp-1 inhibitori za liječenje autoimunih i/ili upalnih poremećaja - Google Patents
Glepp-1 inhibitori za liječenje autoimunih i/ili upalnih poremećaja Download PDFInfo
- Publication number
- HRP20110875T1 HRP20110875T1 HR20110875T HRP20110875T HRP20110875T1 HR P20110875 T1 HRP20110875 T1 HR P20110875T1 HR 20110875 T HR20110875 T HR 20110875T HR P20110875 T HRP20110875 T HR P20110875T HR P20110875 T1 HRP20110875 T1 HR P20110875T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- benzyl
- ethynyl
- butylphenyl
- acid
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract 10
- 230000001363 autoimmune Effects 0.000 title claims abstract 5
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract 5
- 208000023275 Autoimmune disease Diseases 0.000 title claims 4
- 239000003814 drug Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- -1 n-butylphenyl Chemical group 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- OHVAYRLYXQJTHU-UHFFFAOYSA-N 5-[[[4-[2-(4-butylphenyl)ethynyl]phenyl]methyl-(3-cyclopentylpropanoyl)amino]methyl]-2-hydroxybenzoic acid Chemical compound C1=CC(CCCC)=CC=C1C#CC(C=C1)=CC=C1CN(C(=O)CCC1CCCC1)CC1=CC=C(O)C(C(O)=O)=C1 OHVAYRLYXQJTHU-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- YBTZOZVXBUKADH-UHFFFAOYSA-N C(C)(C)(C)C1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=CC3=CC=CC=C23)C=C1 Chemical compound C(C)(C)(C)C1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=CC3=CC=CC=C23)C=C1 YBTZOZVXBUKADH-UHFFFAOYSA-N 0.000 claims 1
- IHHUDSVZUGXWPQ-UHFFFAOYSA-N C(C1=CC=CC=C1)OCC(=O)N(C=1C=CC(=C(C(=O)O)C1)O)CC1=CC=C(C=C1)C#CC1=CC=C(C=C1)CCCC.O1COC2=C1C=CC(=C2)C(=O)N(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC Chemical compound C(C1=CC=CC=C1)OCC(=O)N(C=1C=CC(=C(C(=O)O)C1)O)CC1=CC=C(C=C1)C#CC1=CC=C(C=C1)CCCC.O1COC2=C1C=CC(=C2)C(=O)N(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC IHHUDSVZUGXWPQ-UHFFFAOYSA-N 0.000 claims 1
- DIBFDPIZKGZMKE-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(C(=O)N(CCCCCC)CC=2C=CC(=C(C(=O)O)C2)O)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(=O)C=2C=CC(=C(C(=O)O)C2)O)CCCCCC)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(C(=O)N(CCCCCC)CC=2C=CC(=C(C(=O)O)C2)O)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(=O)C=2C=CC(=C(C(=O)O)C2)O)CCCCCC)C=C1 DIBFDPIZKGZMKE-UHFFFAOYSA-N 0.000 claims 1
- BNPQVHWHOFINLM-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(CCCCC)=O)CC2=CC=C(OCC(=O)O)C=C2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(CCCCC)=O)CC=2C=CC(=C(C(=O)O)C2)O)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(CCCCC)=O)CC2=CC=C(OCC(=O)O)C=C2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C(CCCCC)=O)CC=2C=CC(=C(C(=O)O)C2)O)C=C1 BNPQVHWHOFINLM-UHFFFAOYSA-N 0.000 claims 1
- DFLJDEJQVGHWLZ-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)F)C(CCC2CCCC2)=O)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(CCCCC)=O)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)F)C(CCC2CCCC2)=O)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(CCCCC)=O)C=C1 DFLJDEJQVGHWLZ-UHFFFAOYSA-N 0.000 claims 1
- YIXWMABCRXWGOE-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(=O)C2CCCCC2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)C(CC(C)(C)C)=O)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(=O)C2CCCCC2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)C(CC(C)(C)C)=O)C=C1 YIXWMABCRXWGOE-UHFFFAOYSA-N 0.000 claims 1
- LJXIXJQODKIPFU-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)C)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCCCC)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)C)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCCCC)C=C1 LJXIXJQODKIPFU-UHFFFAOYSA-N 0.000 claims 1
- YSYAJVNFQKDLQC-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCC(C)(C)C)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CC2CCCC2)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCC(C)(C)C)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CC2CCCC2)C=C1 YSYAJVNFQKDLQC-UHFFFAOYSA-N 0.000 claims 1
- GIAXQDINCGQBHC-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCCCCC)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CCCCCC)C=C1 Chemical group C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CCCCCC)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CCCCCC)C=C1 GIAXQDINCGQBHC-UHFFFAOYSA-N 0.000 claims 1
- RQNVWIHXTALIOC-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)C(=O)C2CCCCC2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(CCC2CCCC2)=O)C=C1 Chemical group C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)C(=O)C2CCCCC2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)C(CCC2CCCC2)=O)C=C1 RQNVWIHXTALIOC-UHFFFAOYSA-N 0.000 claims 1
- VBVAANOIMOPUCM-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)C(CC(C)(C)C)=O)C=C1.C1(=CC=C(C=C1)C(=O)N(C=1C=CC(=C(C(=O)O)C1)O)CC1=CC=C(C=C1)C#CC1=CC=C(C=C1)CCCC)C1=CC=CC=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)C(CC(C)(C)C)=O)C=C1.C1(=CC=C(C=C1)C(=O)N(C=1C=CC(=C(C(=O)O)C1)O)CC1=CC=C(C=C1)C#CC1=CC=C(C=C1)CCCC)C1=CC=CC=C1 VBVAANOIMOPUCM-UHFFFAOYSA-N 0.000 claims 1
- WJLGBRYIXKGMAP-UHFFFAOYSA-N C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CCCC2=CC=CC=C2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(CCC2=CC=C(C=C2)Cl)CC2=CC=C(C(=O)O)C=C2)C=C1 Chemical compound C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)O)CCCC2=CC=CC=C2)C=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(CCC2=CC=C(C=C2)Cl)CC2=CC=C(C(=O)O)C=C2)C=C1 WJLGBRYIXKGMAP-UHFFFAOYSA-N 0.000 claims 1
- BYEXHIFZVAHLIN-UHFFFAOYSA-N C(CCC)N(C=1C=CC(=C(C(=O)O)C1)F)CC1=CC=C(C=C1)C#CC1=CC=CC=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CC2CC2)C=C1 Chemical compound C(CCC)N(C=1C=CC(=C(C(=O)O)C1)F)CC1=CC=C(C=C1)C#CC1=CC=CC=C1.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C=2C=CC(=C(C(=O)O)C2)F)CC2CC2)C=C1 BYEXHIFZVAHLIN-UHFFFAOYSA-N 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010056979 Colitis microscopic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- XBSSHEXJODUHFM-UHFFFAOYSA-N FC1=C(C(=O)O)C=C(C=C1)N(CC1=CC=C(C=C1)C#CC1=CC=CC=C1)CCCCCC.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)CCCCCC)C=C1 Chemical compound FC1=C(C(=O)O)C=C(C=C1)N(CC1=CC=C(C=C1)C#CC1=CC=CC=C1)CCCCCC.C(CCC)C1=CC=C(C=C1)C#CC1=CC=C(CN(C2=CC(=C(C(=O)O)C=C2)O)CCCCCC)C=C1 XBSSHEXJODUHFM-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 206010067953 Radiation fibrosis Diseases 0.000 claims 1
- NXJXTURPOZGJDP-UHFFFAOYSA-N S1C(=CC2=C1C=CC=C2)C(=O)N(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC.C(CCC)C2=CC=C(C=C2)C#CC2=CC=C(CN(C=1C=CC(=C(C(=O)O)C1)O)C(C1=CC=C(C=C1)CCCCCC)=O)C=C2 Chemical compound S1C(=CC2=C1C=CC=C2)C(=O)N(C=2C=CC(=C(C(=O)O)C2)O)CC2=CC=C(C=C2)C#CC2=CC=C(C=C2)CCCC.C(CCC)C2=CC=C(C=C2)C#CC2=CC=C(CN(C=1C=CC(=C(C(=O)O)C1)O)C(C1=CC=C(C=C1)CCCCCC)=O)C=C2 NXJXTURPOZGJDP-UHFFFAOYSA-N 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000008609 collagenous colitis Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000004341 lymphocytic colitis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000003959 neuroinflammation Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106547 | 2005-07-15 | ||
| PCT/EP2006/064288 WO2007009959A1 (en) | 2005-07-15 | 2006-07-14 | Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110875T1 true HRP20110875T1 (hr) | 2011-12-31 |
Family
ID=35423337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110875T HRP20110875T1 (hr) | 2005-07-15 | 2011-11-23 | Glepp-1 inhibitori za liječenje autoimunih i/ili upalnih poremećaja |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20080207722A1 (de) |
| EP (1) | EP1904048B1 (de) |
| JP (1) | JP2009501197A (de) |
| KR (1) | KR20080036084A (de) |
| CN (1) | CN101282719A (de) |
| AT (1) | ATE534380T1 (de) |
| AU (1) | AU2006271682B2 (de) |
| BR (1) | BRPI0613400A2 (de) |
| CA (1) | CA2609929A1 (de) |
| CY (1) | CY1112148T1 (de) |
| DK (1) | DK1904048T3 (de) |
| EA (1) | EA200800342A1 (de) |
| ES (1) | ES2377881T3 (de) |
| HR (1) | HRP20110875T1 (de) |
| IL (1) | IL188735A (de) |
| MX (1) | MX2008000665A (de) |
| NO (1) | NO20080781L (de) |
| PL (1) | PL1904048T3 (de) |
| PT (1) | PT1904048E (de) |
| RS (1) | RS52116B (de) |
| SI (1) | SI1904048T1 (de) |
| UA (1) | UA94049C2 (de) |
| WO (1) | WO2007009959A1 (de) |
| ZA (1) | ZA200710497B (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54707B1 (en) * | 2009-07-30 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | TREATMENT OF CROWN LAKVINIMOD DISEASE |
| WO2012149049A1 (en) * | 2011-04-26 | 2012-11-01 | Indiana University Research And Technology Corporation | Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of mycobacterium tuberculosis |
| EP3394041A1 (de) * | 2015-12-22 | 2018-10-31 | Syngenta Participations AG | Mikrobiozide oxadiazolderivate |
| CN107936110B (zh) * | 2017-11-07 | 2021-06-22 | 潍坊医学院 | 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制 |
| US11192850B2 (en) * | 2020-04-06 | 2021-12-07 | Purdue Research Foundation | N-aryl oxamic acids |
| KR20230116709A (ko) * | 2022-01-27 | 2023-08-04 | 주식회사 비보존 | 정신질환의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| EP0727406B1 (de) * | 1995-02-16 | 2001-09-05 | MERCK PATENT GmbH | Vinylenverbindungen und flüssigkristallines Medium |
| JPH11506425A (ja) * | 1995-04-21 | 1999-06-08 | 第一製薬株式会社 | エチニルチアゾール誘導体 |
| FR2762514B1 (fr) * | 1997-04-29 | 1999-10-22 | Sanofi Sa | Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation |
| CA2462442A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
| EP1439834A1 (de) * | 2001-10-30 | 2004-07-28 | Applied Research Systems ARS Holding N.V. | Oxindolhydrazid-modulatoren der protein-tyrosin-phosphatasen (ptps) |
| JP2003171305A (ja) * | 2001-11-30 | 2003-06-20 | Yunie:Kk | 糖尿病改善治療剤 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| CN100410236C (zh) * | 2002-01-29 | 2008-08-13 | 雪兰诺实验室有限公司 | 作为蛋白酪氨酸磷酸酶调节剂的取代亚甲基酰胺衍生物 |
| WO2004080377A2 (en) | 2003-03-11 | 2004-09-23 | Neurosearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| ES2337150T3 (es) * | 2003-07-21 | 2010-04-21 | Merck Serono Sa | Alquinilaril carboxamidas. |
| WO2005007616A1 (en) | 2003-07-23 | 2005-01-27 | Warner-Lambert Company Llc | Diphenylamino ketone derivatives as mek inhibitors |
| KR101194968B1 (ko) * | 2004-04-07 | 2012-10-25 | 메르크 세로노 에스.에이. | Ｐｔｐ 1-ｂ 저해제로서의 1,1’-(1,2-에틴디일)비스-벤젠유도체 |
-
2006
- 2006-07-14 US US11/916,097 patent/US20080207722A1/en not_active Abandoned
- 2006-07-14 RS RS20110580A patent/RS52116B/en unknown
- 2006-07-14 JP JP2008520891A patent/JP2009501197A/ja active Pending
- 2006-07-14 KR KR1020087003525A patent/KR20080036084A/ko not_active Application Discontinuation
- 2006-07-14 SI SI200631196T patent/SI1904048T1/sl unknown
- 2006-07-14 CN CNA2006800336726A patent/CN101282719A/zh active Pending
- 2006-07-14 CA CA002609929A patent/CA2609929A1/en not_active Abandoned
- 2006-07-14 PT PT06777795T patent/PT1904048E/pt unknown
- 2006-07-14 AU AU2006271682A patent/AU2006271682B2/en not_active Expired - Fee Related
- 2006-07-14 AT AT06777795T patent/ATE534380T1/de active
- 2006-07-14 ZA ZA200710497A patent/ZA200710497B/xx unknown
- 2006-07-14 EA EA200800342A patent/EA200800342A1/ru unknown
- 2006-07-14 PL PL06777795T patent/PL1904048T3/pl unknown
- 2006-07-14 DK DK06777795.3T patent/DK1904048T3/da active
- 2006-07-14 EP EP06777795A patent/EP1904048B1/de active Active
- 2006-07-14 MX MX2008000665A patent/MX2008000665A/es active IP Right Grant
- 2006-07-14 UA UAA200800236A patent/UA94049C2/ru unknown
- 2006-07-14 ES ES06777795T patent/ES2377881T3/es active Active
- 2006-07-14 WO PCT/EP2006/064288 patent/WO2007009959A1/en active Application Filing
- 2006-07-14 BR BRPI0613400-9A patent/BRPI0613400A2/pt not_active IP Right Cessation
-
2008
- 2008-01-13 IL IL188735A patent/IL188735A/en not_active IP Right Cessation
- 2008-02-13 NO NO20080781A patent/NO20080781L/no not_active Application Discontinuation
-
2011
- 2011-11-23 HR HR20110875T patent/HRP20110875T1/hr unknown
- 2011-12-14 CY CY20111101240T patent/CY1112148T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK1904048T3 (da) | 2011-12-19 |
| EA200800342A1 (ru) | 2008-08-29 |
| SI1904048T1 (sl) | 2012-01-31 |
| AU2006271682B2 (en) | 2012-07-05 |
| PL1904048T3 (pl) | 2012-04-30 |
| JP2009501197A (ja) | 2009-01-15 |
| IL188735A (en) | 2012-07-31 |
| ES2377881T3 (es) | 2012-04-02 |
| MX2008000665A (es) | 2008-03-13 |
| US20080207722A1 (en) | 2008-08-28 |
| RS52116B (en) | 2012-08-31 |
| AU2006271682A1 (en) | 2007-01-25 |
| UA94049C2 (ru) | 2011-04-11 |
| EP1904048A1 (de) | 2008-04-02 |
| PT1904048E (pt) | 2011-12-19 |
| CY1112148T1 (el) | 2015-11-04 |
| EP1904048B1 (de) | 2011-11-23 |
| ATE534380T1 (de) | 2011-12-15 |
| BRPI0613400A2 (pt) | 2011-01-11 |
| NO20080781L (no) | 2008-02-13 |
| IL188735A0 (en) | 2008-12-29 |
| CN101282719A (zh) | 2008-10-08 |
| ZA200710497B (en) | 2009-04-29 |
| CA2609929A1 (en) | 2007-01-25 |
| WO2007009959A1 (en) | 2007-01-25 |
| KR20080036084A (ko) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110875T1 (hr) | Glepp-1 inhibitori za liječenje autoimunih i/ili upalnih poremećaja | |
| JP2004501962A5 (de) | ||
| HRP20160462T1 (hr) | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1 | |
| JP4937479B2 (ja) | 好中球のｉｌ−８誘発走化性の阻害に有用なアミド | |
| JP5049267B2 (ja) | ベンズイソオキサゾールピペラジン化合物およびその使用方法 | |
| HRP20120505T1 (hr) | Supstituirani n fenilmetil oksoprolin amidi kao antagonisti receptora p x i postupci njihove upotrebe | |
| RU2356893C2 (ru) | Ингибиторы фосфодиэстеразы 4 | |
| US7935832B2 (en) | Pyrrole and isoindole carboxamide derivatives as P2X7 modulators | |
| HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
| HRP20191953T1 (hr) | DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CXCR1 i p40 | |
| US9926276B2 (en) | Substituted benzamides with activity towards EP4 receptors | |
| HRP20141048T1 (hr) | Spojevi, pripravci i metode | |
| RU2003103286A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| HRP20090685T1 (hr) | Supstituirani derivati morfolina i tiomorfolina | |
| CA2532067A1 (en) | N-methyle-substituted benzamidazoles | |
| JP2012523440A5 (de) | ||
| JP2014502979A5 (de) | ||
| NZ573832A (en) | N-(4-{ 2-[4-aryl-piperazin-1-yl]ethyl} cyclohexyl)-acetamide derivatives for the treatment of neuropsychiatric disorders | |
| CN1432009A (zh) | 治疗疼痛的羟苯基－亚哌啶－4－基－甲基－苯甲酰胺衍生物 | |
| JP2010523623A (ja) | Ｐ２ｘ７調節因子としてのピラゾール誘導体 | |
| RS54165B1 (en) | NEW LIGANDS FOR THE ESTROGENIC RECEPTOR | |
| JP2004525112A (ja) | 多形核細胞及び単核細胞の走化性の阻害剤としてのｒ−２−アリール−プロピオン酸のオメガ−アミノアルキルアミド | |
| JP2010522710A (ja) | Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体 | |
| CA2758474A1 (en) | Novel p2x7r antagonists and their use | |
| JP2003516377A5 (de) |